The collaboration between CARER and Wholeleaf aims to offer an integrated approach to cancer patients, combining services and products to optimize their well-being
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Advances clinical research capabilities with leading regulatory grade registries platform
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Subscribe To Our Newsletter & Stay Updated
